Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 424

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Radioembolization for Unresectable Neuroendocrine Hepatic Metastases Using Resin 90Y-Microspheres: Early Results in 148 Patients

Kennedy, Andrew S., Dezarn, William A., McNeillie, Patrick, Coldwell, Doug, Nutting, Charles, Carter, Dennis, Murthy, Ravi, Rose, Steven, Warner, Richard R. P., Liu, David, Palmedo, Holger, Overton, Carroll, Jones, Bonita, Salem, Riad·2008·American Journal of Clinical Oncology

Abstract

PURPOSE: The use of 90Y-microspheres to treat unresectable liver metastases originating from a variety of neuroendocrine tumors was reviewed. MATERIALS AND METHODS: This is a retrospective review from 10 institutions of patients given 90Y-microsphere therapy for neuroendocrine hepatic metastases. Physical, radiographic, biochemical, and clinical factors associated with treatment and response were examined. All patients were followed with laboratory and imaging studies at regular intervals until death, or censured whether other therapy was given after brachytherapy. Toxicities (acute and late) were recorded, and survival of the group determined. RESULTS: A total of 148 patients were treated with 185 separate procedures. The median age was 58 years (26-95 years) at treatment with median performance status of Eastern Cooperative Oncology Group (0). The median activity delivered was 1.14 GBq (0.33-3.30 GBq) with a median of 99% of the planned activity able to be given (38.1%-147.4%). There were no acute or delayed toxicity of Common Terminology Criteria for Adverse Events v3.0 grade 3 in 67% of patients, with fatigue (6.5%) the most common side effect. Imaging response was stable in 22.7%, partial response in 60.5%, complete in 2.7% and progressive disease in 4.9%. No radiation liver failure occurred. The median survival is 70 months. CONCLUSION: Radioembolization with 90Y-microspheres to the whole liver, or lobe with single or multiple fractions are safe and produce high response rates, even with extensive tumor replacement of normal liver and/or heavy pretreatment. The acute and delayed toxicity was very low without a treatment related grade 4 acute event or radiation induced liver disease in this modest-sized cohort. The significant objective response suggests that further investigation of this approach is warranted.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/coc.0b013e31815e4557

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Cited by

See all 424

Metadata

Authors
Kennedy, A. S., Dezarn, W. A., McNeillie, P., Coldwell, D., Nutting, C., Carter, D., Murthy, R., Rose, S., Warner, R. R. P., Liu, D., Palmedo, H., Overton, C., Jones, B., & Salem, R.
Venue
American Journal of Clinical Oncology
Published
2008-06
Volume
31
Issue
3
Pages
271-279
ISSN
0277-3732 (ISSN-L)
OpenAlex
W2069999129
Cited by
424
References
40
FWCI
20.37
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Radioembolization for Unresectable Neuroendocrine Hepatic Metastases Using Resin 90Y-Microspheres: Early Results in 148 Patients. https://app.cochat.ai/papers/10.1097/coc.0b013e31815e4557
The paper
Kennedy, A. S., Dezarn, W. A., McNeillie, P., Coldwell, D., Nutting, C., Carter, D., Murthy, R., Rose, S., Warner, R. R. P., Liu, D., Palmedo, H., Overton, C., Jones, B., & Salem, R. (2008). Radioembolization for Unresectable Neuroendocrine Hepatic Metastases Using Resin 90Y-Microspheres: Early Results in 148 Patients. American Journal of Clinical Oncology. https://doi.org/10.1097/coc.0b013e31815e4557

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.